Coviglobin

Instructions for Use of Coviglobin
Description

Coviglobin is a purified and concentrated gamma-globulin fraction isolated from the blood plasma of convalescent individuals who have recovered from COVID-19.
The preparation contains specific antibodies against SARS-CoV-2 coronavirus proteins.

Sodium benzoate is added to the preparation at a dose of 1 mg/ml as a preservative and an additional mucolytic agent.

The preparation is a transparent, opalescent liquid with a yellowish tint, supplied in ampoules or vials containing 2–10 ml.

Biological and Immunological Properties

Coviglobin contains specific polyvalent antibodies that suppress the activity of the SARS-CoV-2 coronavirus in the human body.

In the lungs, antibodies may remain active for 7–10 days or longer.

Even in cases of overdose, the preparation is considered safe, non-reactogenic, and non-toxic. However, in rare cases, allergic reactions may occur.

Indications for Use

Coviglobin is intended for the prevention and treatment of COVID-19 in humans at the earliest stages of the disease (from 1 to 6 days after the first symptoms appear).

For prophylactic purposes, the preparation is recommended for healthy individuals who have been in contact with infected persons or when there is suspected exposure to infection in epidemic areas.

Previous vaccination against COVID-19 is not a contraindication to the use of Coviglobin.

Method of Administration and Dosage

Coviglobin is administered in aerosol form, generated using a nebulizer or other inhalation device.

For administration:

Draw 2–3 ml of Coviglobin from the ampoule (or vial) into a syringe.

Transfer the solution into the nebulizer chamber.

Turn on the device.

The patient puts on a mask and inhales the aerosol with short, rapid deep breaths.

Initially, take 2–3 deep inhalations, then stop the device for 5–7 minutes.

If no allergic reactions occur during this time, the device is turned on again and the patient continues inhaling the Coviglobin aerosol for 5–10 minutes.

The inhaled dose for adults is 2–3 ml.

For treatment, Coviglobin is administered once during the early stage of the disease (1–6 days after the onset of symptoms).

For prophylactic purposes, it is also administered once to healthy individuals at risk of infection.

If exposure risk occurs repeatedly, Coviglobin may be administered multiple times, once for each case of exposure.

Dosage Form

Coviglobin is produced in ampoules or vials of 2–10 ml, packaged in cardboard boxes together with instructions for use.

Storage and Transportation Conditions

Store in a dry, dark place at a temperature of (5 ± 3)°C.

Coviglobin that has been frozen once but has not changed its physical properties remains suitable for use.

The preparation may be transported by all types of transport at a temperature of (5 ± 3)°C.

Shelf Life

2 years

Do not use the preparation after the expiration date indicated on the package.

Keep out of reach of children.

Complaints and Contact Information

Complaints regarding the physical or other properties of Coviglobin should be sent to:

State Center for Expertise and Standardization of Medicines and Medical Equipment
Ministry of Health of the Republic of Uzbekistan

Address:
100002, Tashkent, Uzbekistan
Ozod Street, Q. Umarov Street 16
Tel: +998 71 244-48-23
Fax: +998 71 244-48-25

as well as to the manufacturer:

Tashkent Research Institute of Vaccines and Sera
Address: 37 Ch. Aytmatov Street, Tashkent, Uzbekistan.

Cases of increased reactogenicity should be reported by phone:
+998 71 234-77-97, followed by submission of relevant materials.